A Celsion Corp. investor sued it in Delaware, seeking to investigate the circumstances surrounding failed clinical trials that cratered its stock price and threatened its Nasdaq listing, including what the company’s leaders knew while hyping an experimental cancer drug.
The lawsuit, filed late Tuesday in Delaware Chancery Court, requests internal company files shedding light on the phase III trials of ThermoDox, a potential liver cancer treatment the company put through two costly studies since 2012.
“The company and certain of its fiduciaries claimed that ThermoDox” could increase survival rates, the complaint says. “Unfortunately for the company’s stockholders and those suffering ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.